Statement: Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 18/364 (4.95%)   Febrile neutropenia 3/364 (0.82%)   Atrial fibrillation 1/364 (0.27%)   Cardio-respiratory arrest 1/364 (0.27%)   Sinus bradycardia 1/364 (0.27%)   Ventricular extrasystoles 0/364 (0.00%)   Enterocolitis 0/364 (0.00%)   Faecaloma 0/364 (0.00%)   Gastric ulcer perforation 0/364 (0.00%)   Gastrointestinal toxicity 0/364 (0.00%)   Pancreatitis acute 0/364 (0.00%) Adverse Events 2:   Total: 5/361 (1.39%)   Febrile neutropenia 0/361 (0.00%)   Atrial fibrillation 0/361 (0.00%)   Cardio-respiratory arrest 0/361 (0.00%)   Sinus bradycardia 0/361 (0.00%)   Ventricular extrasystoles 0/361 (0.00%)   Enterocolitis 0/361 (0.00%)   Faecaloma 0/361 (0.00%)   Gastric ulcer perforation 0/361 (0.00%)   Gastrointestinal toxicity 1/361 (0.28%)   Pancreatitis acute 0/361 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 6/25 (24.00%)   Neutropenia *3/25 (12.00%)   Anemia *0/25 (0.00%)   Febrile Neutropenia *0/25 (0.00%)   Chest Pain *0/25 (0.00%)   Diarrhea *1/25 (4.00%)   Fatigue *1/25 (4.00%)   Liver Tests *0/25 (0.00%)   Neuropathy *0/25 (0.00%)   Syncope *0/25 (0.00%)   Hand and Foot Syndrome *1/25 (4.00%) Adverse Events 2:   Total: 11/26 (42.31%)   Neutropenia *3/26 (11.54%)   Anemia *1/26 (3.85%)   Febrile Neutropenia *1/26 (3.85%)   Chest Pain *1/26 (3.85%)   Diarrhea *1/26 (3.85%)   Fatigue *0/26 (0.00%)   Liver Tests *1/26 (3.85%)   Neuropathy *1/26 (3.85%)   Syncope *1/26 (3.85%)   Hand and Foot Syndrome *1/26 (3.85%)